Castle Biosciences Signs Option Agreement With MD Anderson Cancer Center
Castle Biosciences, a cancer diagnostics company, has signed an option agreement for a brain cancer test with the University of Texas MD Anderson Cancer Center.
The brain cancer test is a molecular diagnostic test developed and validated at The University of Texas MD Anderson Cancer Center to prospectively demonstrate responsiveness to treatment for glioblastoma multiforme, the most common form of primary brain cancer.
This diagnostic test, developed and validated at MD Anderson Cancer Center with early collaborations from other leading US institutions, brings the potential to prospectively stratify a given patient’s likelihood to respond to standard treatment based upon the cancer’s genetic footprint.
Derek Maetzold, president and CEO of Castle Biosciences, said: “In September 2008 we announced our intention to build a molecular diagnostics company that would passionately focus on serving patients with underserved orphan cancers with the intent to provide oncologists with diagnostic information that assists them in adjusting treatment plans based upon the likelihood of an individual patient’s response to treatment – with the ultimate goal of improving their patient’s outcome.”